RedHill Biopharma (RDHL) Retained Earnings (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Retained Earnings data on file, last reported at -$413.8 million in Q4 2025.

• Retained Earnings for Q4 2025 came in at -$413.8 million, changed 0.25% year-over-year; the trailing twelve-month figure through Dec 2025 was -$413.8 million (changed 0.25% YoY), and the FY2025 annual result was -$413.8 million, changed 0.25% from the prior year.
• Retained Earnings advanced to -$413.8 million in Q4 2025 per RDHL's latest filing, from -$418.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$302.3 million in Q1 2021 and troughed at -$433.9 million in Q4 2022.
• A 5-year average of -$387.8 million and a median of -$397.2 million in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2021 and 2023: Retained Earnings sank 35.82% in 2021, then advanced 6.02% in 2023.
• A 5-year view of Retained Earnings shows it stood at -$367.9 million in 2021, then retreated by 17.94% to -$433.9 million in 2022, then grew by 6.02% to -$407.7 million in 2023, then slipped by 1.73% to -$414.8 million in 2024, then gained by 0.25% to -$413.8 million in 2025.
• Business Quant data shows RDHL's Retained Earnings at -$413.8 million in Q4 2025, -$418.1 million in Q2 2025, and -$414.8 million in Q4 2024.